NasdaqCM:IMTXBiotechs
A Fresh Look at Immatics (IMTX) Valuation Following Promising Phase 1a Clinical Results
Immatics (NasdaqCM:IMTX) has released new data from its Phase 1a trials for TCR Bispecifics IMA402 and IMA401, highlighting favorable safety and sustained responses in patients with challenging solid tumors. This update could shape the company’s development path and investor outlook.
See our latest analysis for Immatics.
Momentum has picked up for Immatics, with a robust 61.1% share price return over the past 90 days suggesting investors are responding positively to fresh clinical results and...